We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 100

Russian Antitrust: Supplier obliged to supply distributor competing in same tender
  • Baker McKenzie
  • Russia
  • December 16 2015

A Russian appeal court has upheld Teva’s obligation to supply Copaxone to its distributor to compete against it at tender. The case endorses the


Teva's colourless Copaxone patents found to be novel and inventive
  • Dehns
  • United Kingdom
  • June 2 2015

In a decision dated 21 May 2015, Mr Justice Birss found Teva's patents EP(UK) 2177528 and 2361924, relating to processes for the production of


Teva Pharmaceuticals v. Sandoz: new rules for claim construction review
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • March 12 2015

On January 20, 2015, the Supreme Court changed the standard under which trial court claim construction rulings will be reviewed on appeal, holding


The saga of strict de novo review of patent claim construction comes to an end U.S. Supreme Court tweaks the standard of appellate review
  • Porter Wright Morris & Arthur LLP
  • USA
  • February 6 2015

As we reported last year, one of the issues that has divided the U.S. Court of Appeals for the Federal Circuit (the CAFC) for nearly 20 years is the


Practice considerations post Teva v. Sandoz
  • Sterne Kessler Goldstein & Fox PLLC
  • USA
  • January 30 2015

In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., No. 13-854, slip op. 574 U.S. _ _ (2015), the U.S. Supreme Court ruled that underlying factual


Supreme Court changes standard of review for patent claim construction rulings
  • Burr & Forman LLP
  • USA
  • January 23 2015

In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., the Supreme Court revised the standard of review used by the Federal Circuit for nearly twenty


Supreme Court applies “clear error” review to claim construction (Teva v. Sandoz)
  • Kelley Drye & Warren LLP
  • USA
  • January 23 2015

Earlier this week, in Teva v. Sandoz, the U.S. Supreme Court ruled that the "factual underpinnings" of a district court's claim construction decision


Supreme Court gives more deference to district courts’ factual findings in patent claim construction
  • Hunton & Williams LLP
  • USA
  • January 23 2015

Earlier this week, the US Supreme Court reversed the Federal Circuit in Teva Pharmaceuticals USA, Inc. Sandoz, Inc., No. 13-854 (U.S. Jan. 20, 2015


Supreme Court overturns de novo review of patent claim construction
  • Banner & Witcoff Ltd
  • USA
  • January 22 2015

On Tuesday, in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., the Supreme Court reversed long-standing Federal Circuit precedent under which patent


The Copaxone story in the U.S. and India: U.S. Supreme Court decision
  • Michael Best & Friedrich LLP
  • USA
  • January 22 2015

As an update to our earlier 2014 postings, The Copaxone Story in the U.S. and India, The Copaxone Story in the U.S. and India: An Update, The